MediWound raises $25m

MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds.

In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option, according to an SEC filing.

Cowen & Company and Wells Fargo acted as joint book-running managers for the offering, with Oppenheimer & Co and SunTrust Robinson Humphrey as co-lead managers and Aegis Capital as co-manager.

In January, MediWound  touted data from a phase II trial of its EscharEx drug, which included a follow-up period of 6 months from the last treatment to 3 months from wound closure.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW